Okta To Rally More Than 20%? Here Are 10 Top Analyst Forecasts For Thursday

Shares of semiconductor companies are trading lower as inflation concerns and elevated oil prices push U.S. and global bond yields higher, raising concerns that the Federal Reserve could tighten monetary policy later this month. Higher rates can weigh on growth stocks by making future profits less attractive.

Shares of semiconductor and chip companies are trading lower, possibly after Federal Reserve Chairman Warsh's comments on inflation and prices raised rate-hike concerns. The sector may be facing pressure from peer Marvell Technology, as the company pulls back after its FY28 guidance may have failed to meet investor expectations.

Wells Fargo Maintains Overweight on Merck & Co, Raises Price Target to $170

Want $500 a Month in Passive Income? Start With This Brilliant Dividend ETF.

The Schwab U.S. Dividend Equity ETF (SCHD) is recommended as an effective vehicle for generating sustainable passive income through dividends. With a 3.2% yield and a history of increasing annual dividends since 2011, investors would need approximately $187,500 invested to generate $500 monthly in dividend income. The fund focuses on high-quality dividend-paying stocks and has delivered 13.4% annual returns since inception.

BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now?

BioNTech and Moderna, both mRNA vaccine pioneers during the pandemic, are now pivoting to cancer vaccines as COVID revenue declines. Moderna is favored due to stronger recent clinical progress, including positive phase 3 results for its personalized cancer vaccine intismeran autogene and FDA approval for mFLUSIVA flu vaccine. While BioNTech has a deep pipeline including pumitamig, it has yet to deliver comparable phase 3 wins. Moderna's $61.2 billion market cap reflects investor confidence in its near-term commercialization prospects versus BioNTech's $26 billion valuation.

Does Moderna's mRNA Flu Shot Face a New Challenge From GSK?

Moderna secured FDA approval for mFlusiva, the first mRNA-based seasonal flu vaccine, establishing a foothold in the multibillion-dollar flu vaccine market. However, GSK announced plans to advance its own mRNA flu vaccine into phase III trials, which targets two viral proteins (HA and NA) and showed superior immune responses in phase II studies. While GSK's vaccine is still years away from market approval, it could pose a competitive challenge to Moderna's mFlusiva, which currently targets only HA like traditional flu vaccines.